Equities research analysts expect that XBiotech Inc (NASDAQ:XBIT) will report earnings per share of ($0.15) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for XBiotech’s earnings. XBiotech reported earnings of ($0.14) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 7.1%. The business is scheduled to report its next quarterly earnings report on Wednesday, November 13th.
According to Zacks, analysts expect that XBiotech will report full year earnings of ($0.62) per share for the current year. For the next financial year, analysts forecast that the company will report earnings of ($0.86) per share. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for XBiotech.
XBiotech (NASDAQ:XBIT) last released its quarterly earnings data on Friday, August 9th. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.01).
A number of equities analysts recently commented on the stock. Zacks Investment Research reiterated a “sell” rating on shares of XBiotech in a research report on Saturday, October 26th. BidaskClub upgraded shares of XBiotech from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, October 30th. Finally, ValuEngine cut shares of XBiotech from a “hold” rating to a “sell” rating in a research report on Wednesday, October 2nd.
Several hedge funds have recently added to or reduced their stakes in the business. Citadel Advisors LLC purchased a new position in shares of XBiotech in the second quarter valued at about $146,000. Vanguard Group Inc. increased its position in shares of XBiotech by 35.9% in the second quarter. Vanguard Group Inc. now owns 982,420 shares of the biopharmaceutical company’s stock valued at $7,447,000 after acquiring an additional 259,660 shares during the period. A.R.T. Advisors LLC purchased a new position in shares of XBiotech in the second quarter valued at about $101,000. BlackRock Inc. increased its position in shares of XBiotech by 1,037.4% in the second quarter. BlackRock Inc. now owns 1,193,914 shares of the biopharmaceutical company’s stock valued at $9,049,000 after acquiring an additional 1,088,946 shares during the period. Finally, Sofinnova Investments Inc. increased its position in shares of XBiotech by 26.9% in the second quarter. Sofinnova Investments Inc. now owns 331,811 shares of the biopharmaceutical company’s stock valued at $2,515,000 after acquiring an additional 70,420 shares during the period. Hedge funds and other institutional investors own 10.76% of the company’s stock.
XBIT traded up $0.57 on Tuesday, hitting $11.09. The company’s stock had a trading volume of 97,500 shares, compared to its average volume of 156,232. The firm has a market cap of $429.39 million, a P/E ratio of -18.80 and a beta of 0.45. The company’s 50 day simple moving average is $9.76 and its 200-day simple moving average is $8.54. XBiotech has a 12 month low of $3.65 and a 12 month high of $11.74.
XBiotech Company Profile
XBiotech Inc, a pre-market biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company's lead product is bermekimab, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer.
Further Reading: Why is Cost of Capital Important?
Get a free copy of the Zacks research report on XBiotech (XBIT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for XBiotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech and related companies with MarketBeat.com's FREE daily email newsletter.